Mulinare J, Erickson D. Prevention of neural tube defects. Teratology.1997;56:17-18.
CDC. Recommendations for the use of folic acid to reduce the number of cases
of spina bifida and other neural tube defects. MMWR Morb Mortal Wkly Rep.1992;41(RR-14):1-7.
MRC Vitamin Study Research Group. Prevention of neural tube defects. Lancet.1991;338:131-137.
Czeizel AE, Dudas I. Prevention of the first occurrence of neural tube defects by periconceptional
vitamin supplementation. N Engl J Med.1992;327:1832-1835.
Cornel MC, Erickson JD. Comparison of national policies on periconceptional use of folic acid
to prevent spina bifida and anencephaly (SBA). Teratology.1997;55:134-137.
CDC. Knowledge and use of folic acid by women of childbearing age. MMWR Morb Mortal Wkly Rep.1999;48:325-327.
Food and Drug Administration. Food Standards. Federal Register.1996;61:8781-8797.
Gregory III JF. Bioavailability of folate. Eur J Clin Nutr.1997;51(suppl 1):554-559.
Romano PS, Waitzman NJ, Scheffler RM, Pi RD. Folic acid fortification of grain. Am J Public Health.1995;85:667-676.
Freire WB, Hertrampf E, Cortes F. Effect of folic acid fortification in Chile: prelimary results. Eur J Pediatr Surs.2000;10 Suppl 1:42-43.
Adams T, Jeffreson S. Australia implements voluntary folate fortification. Am J Public Health.1996;86:593-594.
Turner LA, McCourt C. Folic acid fortification. CMAJ.1998;158:773-774.
Skeaff M, Mann J. Should folate be added to flour to prevent neural tube defects? N Z Med J.1998;111:417-418.
Daly S, Scott JM. The prevention of neural tube defects. Curr Opin Obstet Gynecol.1998;10:85-89.
Wynn M, Wynn A. Fortification of grain products with folate. Nutr Health.1998;12:147-161.
Committee on Medical Aspects of Food and Nutrition Policy (COMA). Folic acid and the prevention of disease. London, England: Department of Health; 2000.
Tolson GC, Barnes JM, Gay GA, Kowaleski JL. The 1989 revision of the US standard certificates and reports. Vital Health Stat.June 1991;No.28:1-34. DHHS publication PHS 91-1465.
Freedman MA, Gay GA, Brockert JE, Potrzebowski PW, Rothwell CJ. The 1989 revisions of the US standard certificates of live birth and
death and the US standard report of fetal death. Am J Public Health.1988;78:168-172.
Taffel SM, Ventura SJ, Gay GA. Revised US certificate of birth. Birth.1989;16:188-193.
Watkins ML, Edmonds L, McClearn A, Mullins L, Mulinare J, Khoury M. The surveillance of birth defects. Am J Public Health.1996;86:731-734.
Piper JM, Mitchel EF, Snowden M, Hall C, Adams M, Taylor P. Validation of the 1989 Tennessee birth certificates using maternal
and newborn hospital records. Am J Epidemiol.1993;137:758-768.
Olsen CL, Polan AK, Cross PK. Case ascertainment for state-based birth defects registries. Paediatr Perinat Epidemiol.1996;10:161-174.
Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine
concentrations. N Engl J Med.1999;340:1449-1454.
Lawrence JM, Petitti DB, Watkins M, Umekubo MA. Trends in serum folate after food fortification. Lancet.1999;354:915-916.
Rosenfield A. Women's reproductive health. Am J Obstet Gynecol.1993;169:128-133.
Cohen SA, Saul R. The campaign against partial-birth abortion. Guttmacher Rep Public Policy.1998;1:6-10.
Ventura SJ, Martin JA, Curtin SC, Mathews TJ, Park MM. Births: Final Data for 1998. National Vital Statistics Report. Hyattsville, Md: National Center
for Health Statistics; 2000. Vol 48. No 3.
Crowder SV. Average run lengths of exponentially weighted moving average charts. J Qual Technol.1987;19:161-164.
CDC. Folate status in women of childbearing age-United States, 1999. MMWR Morb Mortal Wkly Rep.2000;49:962-965.
Watkins ML, Erickson JD, Mulinare JRE. The effect of folic acid fortification on plasma folate and total homocysteine
concentrations. N Engl J Med.1999;341:923-924.
Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and neural tube defects. JAMA.1995;274:1698-1702.
Wald NJ, Law M, Jordan R. Folic acid food fortification to prevent neural-tube defects. Lancet.1998;351:834.
Daly S, Mills JL, Molloy AM.
et al. Minimum effective dose of folic acid for food fortification to prevent
neural-tube defects. Lancet.1997;350:1666-1669.
Rader JI, Weaver CM, Angyal G. Total folate in enriched cereal-grain products in the United States
following fortification. Food Chem.2000;70:275-289.
Hook EB, Czeizel AE. Can terathanasia explain the protective effect of folic-acid supplementation
on birth defects? Lancet.1997;350:513-515.
Nelen W, Blom H, Steegers E, Den Heijer M, Thomas C, Eskes T. Homocysteine and folate levels as risk factors for recurrent early
pregnancy loss. Obstet Gynecol.2000;95:519-524.
Wald NJ, Hackshaw AK. Folic acid and miscarriage. Am J Med Genet.2001;98:204.
Grevengood C, Shulman LP, Dungan JS.
et al. Severity of abnormality influences decision to terminate pregnancies
affected with fetal neural tube defects. Fetal Diagn Ther.1994;9:273-277.
Pryde PG, Isada NB, Hallak M, Johnson MP, Odgers AE, Evans MI. Determinants of parental decision to abort or continue after non-aneuploid
ultrasound-detected fetal abnormalities. Obstet Gynecol.1992;80:52-56.
Roberts HE, Moore CA, Cragan JD, Fernhoff PM, Khoury MJ. Impact of prenatal diagnosis on the birth prevalence of neural tube
defects, Atlanta, 1990-1991. Pediatrics.1995;96:880-882.
Velie EM, Shaw GM. Impact of prenatal diagnosis and elective termination on prevalence
and risk estimates of neural tube defects in California, 1989-1991. Am J Epidemiol.1996;144:473-479.
Allen WP, Stevenson RE, Thompson SJ, Dean JH. The impact of prenatal diagnosis on surveillance. Prenat Diagn.1996;16:531-535.
Forrester MB, Merz RD, Yoon PW. Impact of prenatal diagnosis and elective termination on the prevalence
of selected birth defects in Hawaii. Am J Epidemiol.1998;148:1206-1211.